Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2131 to 2140 of 2733 total matches.
A New Indication for Esketamine Nasal Spray (Spravato)
The Medical Letter on Drugs and Therapeutics • Sep 21, 2020 (Issue 1607)
for
treatment-resistant depression,1 has now been
approved for treatment of depressive symptoms in
adults ...
Esketamine (Spravato – Janssen), an intranasal
N-methyl-D-aspartate (NMDA) receptor antagonist
that was previously approved by the FDA for treatmentresistant
depression,1 has now been approved for
treatment of depressive symptoms in adults with
major depressive disorder (MDD) and acute suicidal
ideation or behavior. Esketamine is the S-enantiomer
of the anesthetic ketamine (Ketalar, and generics).
It is the first drug to be approved for this indication.
Most clinical trials of antidepressants have excluded
patients with acute suicidal ideation.
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
and maintenance of memory.1
EFFICACY — Animals – Some PDE5 inhibitors have
been shown to improve memory ...
A reader asked us to review use of the
phosphodiesterase-5 (PDE5) inhibitor sildenafil for
treatment of Alzheimer's disease (AD).
In Brief: Olaparib (Lynparza) for High-Risk Early Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
, pancreatic, and
prostate cancers.1,2 It was previously approved for
treatment of adults with deleterious ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has been
approved by the FDA for adjuvant treatment of adults
with deleterious or suspected deleterious germline
BRCA-mutated (gBRCAm), human epidermal growth
factor receptor 2 (HER2)-negative, high-risk early
breast cancer who received prior neoadjuvant or
adjuvant chemotherapy. The drug was previously
approved for treatment of adults with deleterious
or suspected deleterious gBRCAm, HER2-negative
metastatic breast cancer who received chemotherapy
in the neoadjuvant, adjuvant, or metastatic...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e77-8 doi:10.58347/tml.2023.1674j | Show Introduction Hide Introduction
In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
)-negative, high-risk
early breast cancer who received prior neoadjuvant
or adjuvant chemotherapy.1 It had ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has now
been approved by the FDA for use in combination
with abiraterone (Zytiga, and others) and either
prednisone or prednisolone for treatment of adults
with deleterious or suspected deleterious BRCA-mutated
(BRCAm) metastatic castration-resistant
prostate cancer (mCRPC). Olaparib was previously
approved by the FDA for treatment of adults with
deleterious or suspected deleterious germline or
somatic homologous recombinant repair (HRR) genemutated
mCRPC who progressed on prior treatment
with...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7 doi:10.58347/tml.2023.1679g | Show Introduction Hide Introduction
Shockwave Therapy for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
recommend using shockwave therapy only in the setting of a clinical trial.1
THE DEVICE — Low-intensity ...
Low-intensity extracorporeal shockwave therapy
similar to that used to fragment kidney stones or
gallstones is a new option for treatment of erectile
dysfunction that is now being advertised extensively
in the US. It has not been approved by the FDA for
treatment of erectile dysfunction.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):190-1 doi:10.58347/tml.2023.1690d | Show Introduction Hide Introduction
Beqvez — Another Gene Therapy for Hemophilia B
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
to
be approved in the US for treatment of hemophilia B;
Hemgenix was the first.1
AAV = adeno-associated virus ...
Fidanacogene elaparvovec-dzkt (Beqvez – Pfizer),
an adeno-associated virus (AAV) vector-based gene
therapy, has been approved by the FDA for treatment
of adults with moderate to severe hemophilia B who
do not have neutralizing antibodies to AAV serotype
Rh74var and currently receive factor IX prophylaxis
therapy or have had life-threatening hemorrhage or
repeated, serious, spontaneous bleeding episodes.
Beqvez is the second single-dose gene therapy to
be approved in the US for treatment of hemophilia B;
Hemgenix was the first.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):95-6 doi:10.58347/tml.2024.1704d | Show Introduction Hide Introduction
Eroxon — An OTC Gel for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
with nitrates.1-3
Alternatives for management of ED include vacuum
erection devices, intraurethral ...
The FDA has authorized over-the-counter (OTC)
sale of a nonmedicated alcohol-based gel (Eroxon –
Futura) for treatment of erectile dysfunction (ED) in
males ≥22 years old. Eroxon is the only FDA-approved
OTC and topical treatment for erectile dysfunction. It
is also available in the UK and the EU.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):181-2 doi:10.58347/tml.2024.1715c | Show Introduction Hide Introduction
Olezarsen (Tryngolza) for Familial Chylomicronemia Syndrome (online only)
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025 (Issue 1723)
in patients with familial chylomicronemia
syndrome.
Table 1. Pharmacology
Class Apolipoprotein C-III (apoC ...
Olezarsen (Tryngolza – Ionis), an apolipoprotein C-III
(apoC-III)-directed antisense oligonucleotide, has
been approved by the FDA to reduce triglyceride levels
in adults with familial chylomicronemia syndrome
(FCS). It is the first drug to be approved in the US for
this indication.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e43-4 doi:10.58347/tml.2025.1723f | Show Introduction Hide Introduction
Treatment of Clostridioides difficile Infection
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
. Guidelines
on management of CDI have recently been updated.1-3
RISK FACTORS — Common risk factors for CDI ...
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been updated.
Chloroxazone Hepatotoxicity
The Medical Letter on Drugs and Therapeutics • May 10, 1996 (Issue 974)
resulting from any error, inaccuracy or omission. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1 ...
The US Food and Drug Administration (FDA) recently approved a stronger warning about hepatotoxicity in the labeling for chlorzoxazone, a centrally-acting skeletal muscle relaxant.
